// App-Quantinova.ai

2586 : Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies

Researchers

Presenter

  • Regis Peffault De Latour

Principal Investigators

  • Jeffrey Szer

  • Austin G Kulasekararaj

  • Jin Seok Kim

  • Caroline I. Piatek

  • Alexander D. Kulagin

  • Anita Hill

  • Jimmy Wang

  • Ji Yu

  • Masayo Ogawa

  • Hubert Schrezenmeier

  • Jong Wook Lee

Medical Centers

  • SBIM, Hopital Saint-Louis, APHP, Paris, France

  • Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia

  • King’s College Hospital, National Institute of Health Research/Wellcome King’s Clinical Research Facility and King’s College London,London,United Kingdom

  • Division of Cardiology, Department of Internal Medicine, Sevarance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

  • Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA

  • RM Gorbacheva Research Institute, Pavlov University,St Petersburg,Russia

  • Vertex Pharmaceuticals Inc., Boston, MA

  • Vertex Pharmaceuticals Inc., Boston, MA

  • Institute of Transfusion Medicine, University of Ulm, and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm,Ulm,Germany

  • Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Locations

  • France

  • Australia

  • United Kingdom

  • Republic of South Korea

  • United States

  • Russia

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A


Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02946463

  • NCT03056040

Sponsors

  • N/A

Result

  • N/A